CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
|Articles|June 15, 2012
Access, Costs, Quality Vary Widely by Area, Analysis Finds
Advertisement
Source: ModernHealthcare.com
Regions of the Upper Midwest and Northeast ranked higher than communities in the Gulf Coast and South Central states, the report said.
A Commonwealth Fund analysis of more than 40 measures of healthcare access, quality and cost found major differences across 306 U.S. communities. The analysis, which looked at avoidable hospital visits, infant mortality, routine checkups and more than three dozen other measures, also found an association between greater access and better quality and outcomes, according to a newly released report by the health policy not-for-profit.
Advertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
3
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
4
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
5